Similar articles

• Sulfonylureas and platelet function.

  Klaff LJ, Kernoff L, Vinik AI, Jackson WP, Jacobs P. Klaff LJ, et al. Am J Med. 1981 Mar;70(3):627-30. doi: 10.1016/0002-9343(81)90585-4. Am J Med. 1981. PMID: 6782875 Review.
• Changes in platelet aggregation caused by glyburide in diabetic patients.

  De Bellis R, Novoa E, Dol B, Cazerez J, Arroyo G, Balbela B, Navarro A. De Bellis R, et al. Clin Ther. 1984;6(3):335-43. Clin Ther. 1984. PMID: 6426797
• Insulin as a first-line therapy in type 2 diabetes: should the use of sulfonylureas be halted?

  Standl E, Schnell O. Standl E, et al. Diabetes Care. 2008 Feb;31 Suppl 2:S136-9. doi: 10.2337/dc08-s234. Diabetes Care. 2008. PMID: 18227474 No abstract available.
• Diabetes, coronary heart disease and sulphonylureas-not the final word.

  Betteridge DJ, Close L. Betteridge DJ, et al. Eur Heart J. 2000 May;21(10):790-2. doi: 10.1053/euhj.1999.2069. Eur Heart J. 2000. PMID: 10781346 No abstract available.
• [Therapeutic activity of anti-platelet aggregation agents in arterial diseases].

  Delboy C, Jouve R, Escande M, Juhan I, Bouvenot G. Delboy C, et al. Sem Hop Ther. 1977 Nov;53(9):431-40. Sem Hop Ther. 1977. PMID: 341318 Review. French. No abstract available.